Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Immunology
  9. Immunology Not Elsewhere Classified
  11. A Rare Case Of Hemolytic Anemia After Alectinib That Did Not Recur After Switching To Lorlatinib.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Immunology
  9. Immunology Not Elsewhere Classified
  11. A Rare Case Of Hemolytic Anemia After Alectinib That Did Not Recur After Switching To Lorlatinib.

Related Experiment Video

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

406

A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib.

X Tonnar1, Cornelius F Waller1

  • 1Department of Medicine I, Medical Center, University of Freiburg, Freiburg, Germany.

Case Reports in Oncology
|December 1, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Alectinib therapy for ALK-positive lung cancer can cause Coombs-negative hemolytic anemia. This case shows rapid hemoglobin recovery after pausing alectinib and successful treatment with lorlatinib.

Keywords:
ALK mutationAlectinibHemolysisLorlatinib

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

817
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

Related Experiment Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

406
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

817
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Anaplastic Lymphoma Kinase (ALK)-positive lung cancer is a distinct subtype.
  • Alectinib is a tyrosine kinase inhibitor used for ALK-positive lung cancer.
  • Drug-induced hemolytic anemia is a rare but serious adverse effect of some cancer therapies.
Non-small cell lung cancer